Nuq Header

Rethinking the approach to cancer

Nu.Q represents a powerful step-change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.

Nu.Q’s unique technology looks for very early ‘nucleosomic’ markers of cancer

Nu.Q uses an array of simple, cost-effective, and accurate blood tests

These tests identify early stage cells before the cancer spreads

Giving medical professionals increased diagnostic power

Early diagnosis informs and reassures patient

Nu.Q can reduce the strain on over-burdened healthcare systems

X Slider Image

How it works

Cancer leads to irregular levels of uniquely structured nucleosomes in the blood. A nucleosome is a section of DNA wrapped around a core of proteins. Through a simple test, with less than a drop of blood, we are able to detect those unique nucleosomes; and by measuring and analyzing them, our Nu.Q tests can establish whether cancer is present in the patient.

Colorectal Cancer

Volition’s initial Nu. Q™ products are focusing on colorectal cancer. Colorectal cancer is ranked second among all newly diagnosed cancers.

97%

Patients with bowel cancer caught early (at stage I) have an average 97% five-year survival rate. Currently, fewer than one in ten people are diagnosed at stage I

7%

If colorectal cancer is not caught until it has spread (stage IV), the chances of surviving five years or more falls to just 7%

700,000 deaths per year

Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide

X Mandated 2

Mandated screening

In response to the findings on the benefits of early diagnosis, the EU and numerous other countries worldwide have mandated colorectal cancer screening programs. There are currently organised colorectal cancer screening programmes in 14 of the 28 EU states, with a further 10 states offering some form of public or privately accessible screening.

Colorectal Cancer Screening Triage Test

Volition’s first Nu.Q test is the Nu.Q™ colorectal cancer screening triage test. This test works in conjunction with the current standard screening test, the fecal immunochemical test (FIT), used in most colorectal cancer screening programs.

X Screening Image Small

The triage test has demonstrated the potential to reduce colonoscopies by up to 25% while maintaining almost 97% detection of colorectal cancer

Streamlining the diagnostic process

The Nu.Q colorectal cancer screening triage test identifies patients who have received a false positive result on their FIT test. Approximately 95% of people who receive a positive FIT score do not have colorectal cancer due to the test’s detecting blood in stool, not cancer directly. Therefore, the Nu.Q colorectal cancer screening triage test aims to streamline the diagnostic process and ensure that fewer patients are referred for unnecessary colonoscopies. 

Clinical Evidence
News Image 2
Poster ESMO
Screening Image Small
ESMO presentation
Screening Image Small
Novel Serum Nucleosomics Biomarkers for the Detection of Colorectal Cancer
Investor Press
ENDO Poster 2017
Group Slider Fade 3 Group High Res Min
Grey Background Science Board
Grey Background Group High Res Min
Grey Background Board

Our expert team

The Research Team based in Namur bring together years of scientific experience with the passion that is commonplace at Volition. Using their extensive knowledge, the team is dedicated to developing diagnostic tools that will relieve the burden of cancer worldwide; for the patients, the clinical teams and the healthcare systems.

Our Scientific Advisory Board brings together a unique combination of world leaders in the fields of epigenetics, clinical oncology and clinical diagnostics. Together they bring insights, share opinions and act as a knowledgeable sounding board to help us develop our technology and products to meet real clinical needs in line with the very latest scientific thinking.

Dr. Alan Colman
Dr. Alan Colman
Dr. Andreas Ladurner
Dr. Andreas Ladurner
Dr. Jorge Reis-Filho
Dr. Jorge Reis-Filho
Dr. Roland Andersson
Dr. Roland Andersson
Dr. Stuart Blincko
Dr. Stuart Blincko
Dr. Robert Weinzierl
Dr. Robert Weinzierl
Prof. Stefan Holdenrieder
Prof. Stefan Holdenrieder

Our Executive Team are a collective force of distinct individuals but our aim is the same – to save lives by revolutionizing the way cancer is diagnosed.

Cameron Reynolds
Cameron Reynolds President & Chief Executive Officer
Jake Micallef
Jake Micallef PhD MBA Chief Scientific Officer
Gaetan Michel
Gaetan Michel Chief Executive Officer of Belgian Volition SPRL
Jason Terrell
Jason Terrell Chief Medical Officer & Head of U.S. Operations
Louise Day
Louise Day Chief Marketing and Communications Officer
David Kratochvil
David Kratochvil MBA Chief Financial Officer & Treasurer
Rod Rootsaert
Rod Rootsaert Corporate Secretary
Jasmine Kway
Jasmine Kway PhD Vice President, Asia

Our Board of Directors have decades of entrepreneurial, managerial and leadership experience. They are responsible for our strategy, activities, risk management and financial performance.

Cameron Reynolds President & Chief Executive Officer
Dr. Martin C Faulkes Chairman
Dr. Alan Colman Non-Executive Director
Guy Innes Non-Executive Director
Dr. Edward Futcher Non-Executive Director
Dr. Habib Skaff Non-Executive Director
arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus